Pharmacologic preservation of the hemostatic system during cardiac surgery

Annals of Thoracic Surgery

Volumn 72, Issue 5, 2001, Pages

  Levy, Jerrold H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACTIVATED PROTEIN C; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTITHROMBIN III; APROTININ; ARGATROBAN; CLOPIDOGREL; COMPLEMENT INHIBITOR; DANAPAROID; DERMATAN SULFATE; DESMOPRESSIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LYSINE; PENTASACCHARIDE; PEXELIZUMAB; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT HIRUDIN; THROMBOCYTE SLOWING FACTOR; TIROFIBAN; TRANEXAMIC ACID; WARFARIN;

BLEEDING; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; HEART SURGERY; HEMOSTASIS; HUMAN; PATIENT CARE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; INTRAOPERATIVE CARE;

EID: 0035171792     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(01)03218-0     Document Type: Conference Paper

References (59)

1. Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors
2. Molecular and cellular biology of blood coagulation
3. Thrombin hypothesis of thrombus generation and vascular lesion formation
4. Advances in antithrombotic therapy: Novel agents
5. The coagulation cascade: Initiation, maintenance, and regulation
6. Anti-thrombotic agents in coronary artery disease
7. Conversion from chronic to acute coronary heart disease syndromes: Role of platelets and platelet products
8. Systemic inflammatory response syndrome and anti-inflammatory strategies
9. Linkage between inflammation and coagulation: An update on the molecular basis of the crosstalk
10. Thrombin-mediated events implicated in mast cell activation
11. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
12. Heparin
13. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa
14. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations
15. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT
16. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass
17. Low-molecular-weight heparins
18. Low-molecular-weight heparins: An intriguing new twist with profound implications
19. Novel intravenous antithrombins
20. Hemostatic agents and their safety
21. Prospective evaluation of risk of protamine reactions in NPH insulin-dependent diabetics
22. Effects of protamine on histamine release from human lung
23. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa
24. Heparin neutralization by platelet factor 4 and protamine
25. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers
26. Rate of protamine administration: Its effect on heparin reversal and antithrombin recovery after coronary atery surgery
27. Uses of antithrombin III concentrate in congenital and acquired deficiency states
28. Antithrombin III during cardiac surgery: Effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation
29. Transgenically produced recombinant human ATIII enhances the antithrombotic effects of heparin in patients undergoing cardiac surgery
30. In vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy
31. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
32. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor
33. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development
34. Recombinant hirudin (lepirudin) provides safe, and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
35. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time
36. Clinical outcomes of bivalirudin for ischemic heart disease
37. Anticoagulants in acute coronary syndromes
38. Thrombin inhibitors as anticoagulant agents
39. Thrombin hypothesis of thrombus generation and vascular lesion formation
40. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
41. Anticoagulation monitoring during cardiac surgery: A survey of current practice and review of current and emerging techniques
42. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis
43. Heparin-induced thrombocytopenia (HIT). An overview of 230 patients treated with orgaran (Org 10172)
44. Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis
45. Heparin-less cardiopulmonary bypass with ancrod
46. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin
47. Aprotinin: An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery
48. Hemostatic drugs
49. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients
50. A multicenter, placebo-controlled, double-blind trial of aprotinin to reduce blood loss and the requirement of donor blood transfusion in patients undergoing repeat coronary artery bypass grafting
51. International multicenter aprotinin graft patency experience (IMAGE)
52. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints
53. Platelet inhibitors and bleeding in cardiac surgical patients
54. Clopidogrel: A review of its use in the prevention of atherothrombosis
55. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
56. NovoSeven as a universal haemostatic agent
57. Prospective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery
58. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery